J&J shutters PhIII trial for pulmonary hypertension drug, blocking its expanded use as patent expiry looms
Johnson & Johnson has crossed off a Phase III trial from its plans, which was designed to expand the use of hypertension drug Opsumit after …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
